PureTech’s Video Game for ADHD Gets Big Series D Financing
Day One increases term sheet ahead of expected IPO
The maker of the first prescription video game treatment announced it received $110 million in Series D financing Wednesday.
Akili’s EndeavorRx is an FDA-approved video game to improve attention function in children with ADHD. The game is designed to target attentional control systems in the brain and present sensory and motor challenges to activate the nervous systems.
The company was founded by PureTech, the Boston-based biotherapeutics company.